A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

CompletedOBSERVATIONAL
Enrollment

168

Participants

Timeline

Start Date

March 30, 2019

Primary Completion Date

October 22, 2022

Study Completion Date

October 22, 2022

Conditions
Hereditary Angioedema (HAE)
Trial Locations (29)

10029

Mount Sinai, New York

17033

Penn State Hershey Medical Center, Hershey

20815

Institute for Asthma & Allergy - Chevy Chase, Chevy Chase

27704

Duke Asthma, Allergy & Airway Center, Durham

28277

Clinical Research of Charlotte, Charlotte

33613

University of South Florida Asthma, Allergy & Immunology, Tampa

35209

Clinical Research Center of Alabama, Birmingham

45231

Bernstein Clinical Research Center, LLC, Cincinnati

48106

University of Michigan, Ann Arbor

55446

Mid West Immunology Clinic, Plymouth

63141

Washington University, St Louis

66160

University of Kansas Medical Center Research Institute, Inc., Kansas City

75231

AARA Research Center, Dallas

80907

Asthma and Allergy Associates, PC, Colorado Springs

85248

Medical Research of Arizona, Scottsdale

90404

AIRE Medical of Los Angeles, Santa Monica

92122

University of California San Diego, San Diego

97086

Portland Clinical Research/AAIM Care, Happy Valley

98115

Seattle Allergy & Asthma Research Institute, Seattle

06519

Yale University School of Medicine, New Haven

02114-2752

Massachusetts General Hospital, Boston

07109

Riverside Medical Group, Belleville, Belleville

07410

Jay M Kashkin, MD Allergy, Asthma and Immunology, Fair Lawn

T2N 2T9

University of Calgary - Heritage Medical Research Clinic, Calgary

L8S 4K1

McMaster University Health Sciences Center, Hamilton

M5B 1W8

St. Michael's Hospital, Toronto

H2X 0A9

CHUM Hôtel-Dieu, Montreal

G1V 4W2

Clinique Specialisée en Allergie de la Capitale, Québec

00918

Rafael H Zaragoza-Urdaz, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Shire

INDUSTRY